EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Cardiac toxicity associated with pharmacokinetic drug–drug interaction between crizotinib and sofosbuvir/velpatasvir: A case report

Anthia Monribot, Olivier Huillard, Nihel Khoudour iD, Laure-Hélène Préta iD, Benoit Blanchet, Laure Cabanes, Rui Batista, Nicolas Pallet, Laurent Chouchana iD, François Goldwasser, Philippe Sogni, Audrey Thomas-Schoemann iD

British Journal of Clinical Pharmacology · 2023

DOI: 10.1111/bcp.15674 ↗

Kurz gefasst

Fallbericht in der Zeitschrift British Journal of Clinical Pharmacology, 2023. Verfasst von Anthia Monribot und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Cochin Hospital, AP-HP, University of Paris, Paris, France. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Hepatitis C, Chronic, Macrocyclic Compounds, Lung Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This case report describes a pharmacokinetic drug–drug interaction between crizotinib, a tyrosine kinase inhibitor, and sofosbuvir/velpatasvir, a direct‐acting antiviral drug, leading to cardiac toxicity. A 75‐year‐old man, with no cardiovascular history but a diagnosis of metastatic nonsmall cell lung cancer with mesenchymal–epithelial transition exon‐14 deletion and hepatitis C virus infection genotype 1A, received both crizotinib and sofosbuvir/velpatasvir. Crizotinib was well tolerated, but 1 week after sofosbuvir/velpatasvir initiation, the patient experienced bilateral lower‐limb oedema and class III New York Heart Association dyspnoea. We assumed that increased exposure to crizotinib could account for this cardiac toxicity. Drug causality was probable according to the Naranjo scale. We hypothesized a reciprocal interaction between crizotinib and velpatasvir, mediated by both cytochrome 3A4 (CYP3A4) and P‐glycoprotein (P‐gp). Clinicians should be aware of the risk of drug–drug interactions between direct‐acting antiviral agents that inhibit CYP3A4 (glecaprevir) and/or P‐gp (voxilaprevir, velpatasvir) and anticancer tyrosine kinase inhibitors that are mostly CYP3A4 and/or P‐gp substrates (gefitinib, afatinib, erlotinib, crizotinib, ceritinib, lorlatinib, brigatinib, capmatinib etc.).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungHepatitis C, ChronicMacrocyclic CompoundsLung NeoplasmsMaleHumansAgedSofosbuvirAntiviral AgentsCrizotinibCardiotoxicityCytochrome P-450 CYP3AHepacivirusGenotypeDrug Therapy, CombinationBenzimidazolesBenzopyransCarbamatesHeterocyclic Compounds, 4 or More Rings

Stichwörter der Autor:innen

P-glycoproteinanticancer drugscytochrome P450 enzymesdrug interactionstherapeutic drug monitoring

Substanzen

SofosbuvirAntiviral AgentsCrizotinibCytochrome P-450 CYP3AMacrocyclic CompoundsvelpatasvirBenzimidazolesBenzopyransCarbamatesHeterocyclic Compounds, 4 or More Rings

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, Cochin Hospital, AP-HP, University of Paris, Paris, France.
  • Department of Medical Oncology, Cochin Hospital, AP-HP, Université de Paris, Paris, France.
  • Sorbonne Paris Cite, Faculty of Medicine, University of Paris Descartes, France.
  • Department of Pharmacokinetics and Pharmacochemisty, Cochin Hospital, AP-HP, Paris, France; CARPEM, Paris, France.
  • Regional Center of Pharmacovigilance, Department of Pharmacology, Cochin Hospital, AP-HP, Paris, University of Paris, Paris, France.
  • UMR8038 CNRS, U.1268 INSERM, Faculty of Pharmacy, University Paris Descartes, PRES Sorbonne Paris Cité, Paris, France.

ORCID-Profile: Nihel Khoudour, Laure-Hélène Préta, Laurent Chouchana, Audrey Thomas-Schoemann

Zitieren

APA

Monribot, A., Huillard, O., Khoudour, N., Préta, L. H., Blanchet, B., Cabanes, L., Batista, R., Pallet, N., Chouchana, L., Goldwasser, F., Sogni, P., & Thomas-Schoemann, A. (2023). Cardiac toxicity associated with pharmacokinetic drug–drug interaction between crizotinib and sofosbuvir/velpatasvir: A case report. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.15674

Vancouver

Monribot A, Huillard O, Khoudour N, Préta LH, Blanchet B, Cabanes L, et al. Cardiac toxicity associated with pharmacokinetic drug–drug interaction between crizotinib and sofosbuvir/velpatasvir: A case report. British Journal of Clinical Pharmacology. 2023. doi:10.1111/bcp.15674

BibTeX
@article{Monribot2023,
  author = {Monribot, Anthia and Huillard, Olivier and Khoudour, Nihel and Préta, Laure-Hélène and Blanchet, Benoit and Cabanes, Laure and Batista, Rui and Pallet, Nicolas and Chouchana, Laurent and Goldwasser, François and Sogni, Philippe and Thomas-Schoemann, Audrey},
  title = {Cardiac toxicity associated with pharmacokinetic drug–drug interaction between crizotinib and sofosbuvir/velpatasvir: A case report},
  journal = {British Journal of Clinical Pharmacology},
  year = {2023},
  doi = {10.1111/bcp.15674}
}
Kostenlos starten →